Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 501 participants.

Also called NCT03640949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 501 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03640949
  • EudraCT 2017-004773-13
Other papers using this trial's data
  • Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial JAMA, 2021-10-26 DOI, PubMed 34587236, PMC8482303 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03640949. Randomized; quadruple masking; primary purpose treatment. Start 2018-09-17 (actual); primary completion 2021-01-21 (actual). Results posted on 2022-01-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
Acronym
VAM-IHCA
Condition
Heart Arrest
Intervention (Drug)
Vasopressin, Arginine
Intervention (Drug)
Methylprednisolone
Intervention (Drug)
NaCl
Lead sponsor
Lars Wiuff Andersen (class: other)
Collaborator
University of Aarhus (class: other)

Record details

Record id
cardio:ct-nct03640949
Content hash
ec3fa495a4eca6facfcbcd5ab30de4ad012e092ea75aa4d0499c77108423166f